A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.
A phase 2, randomized, vehicle-controlled, double-blind study to assess the efficacy, safety and pharmacodynamics (PD) of topically applied CLS003 in otherwise healthy patients with cutaneous warts.
Cutaneous Warts
DRUG: CLS003|DRUG: Furosemide|DRUG: Digoxin|DRUG: Vehicle topical
Change from baseline in morphological wart assessment, Days 14, 28, 42, 70, 98|Change from baseline in Wart size and morphology assessment by standardized clinical photography, Days 14, 28, 42, 70, 98|Change from baseline in HPV viral load assessment of target lesions by quantitative PCR, Days 14, 28, 42, 70, 98|Reduction in wart size, Days 14, 28, 42, 70, 98|Change in the HPV viral load, Days 14, 28, 42, 70, 98|Change from baseline in mean HPV viral load, Days 14, 28, 42, 70, 98|Percent clearance of warts, Days 14, 28, 42, 70, 98
Adverse event to evaluate safety and tolerability of CLS003, Days 0-98
A phase 2, randomized, vehicle-controlled, double-blind study to assess the efficacy, safety and pharmacodynamics (PD) of topically applied CLS003 in otherwise healthy patients with cutaneous warts.